How Does AOD 9604 Compare to Ozempic and GLP 1s? AOD 9604 'not performance enhancing': Essendon The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The FDA has repeatedly flagged AOD 9604 as a compound of concern. It was placed on the Category 2 list in 2023 bulk drug substances in compounding that may present significant